The article discusses the role of minimally invasive surgery (MIS) in the treatment of T4 non-small-cell lung cancers (NSCLC), which are locally advanced tumors. The article highlights that MIS is feasible and safe in properly selected patients, with comparable outcomes to traditional open surgery. However, there are still unanswered questions regarding which subtypes of T4 tumors can be effectively managed with MIS. The article emphasizes the importance of a multimodality approach and the need for further research to determine the optimal use of MIS in the treatment of T4 NSCLC. [Extracted from the article]